Abstract: An observed surrogate endpoint is often used to predict treatment effect on an unobserved true endpoint when the true endpoint is difficult or expensive to be measured. Although there have been several criteria for surrogate endpoints, they cannot avoid the surrogate paradox, which means that a treatment has a positive effect on a surrogate and the surrogate has a positive effect on an endpoint, but the treatment has a negative effect on the endpoint. To avoid the surrogate paradox, some investigators provided criteria for a single surrogate which blocks the path from the treatment to the endpoint. This requires that there is only a single path from treatment to endpoint and the surrogate can block the single path. However, in many applications, a treatment may affect an endpoint through several paths. In this paper, we propose some criteria for multiple surrogates. We make use of stochastic orders of random vectors to give criteria for multiple surrogates to avoid the surrogate paradox and to predict the sign of treatment effect on the unobserved true endpoint. Further under the conditional independence of the treatment and the true endpoint given the multiple surrogates, we propose some sufficient conditions for the sign equivalence of treatment effects on the surrogates and on the true endpoint. Furthermore, Statistica Sinica: Newly accepted Paper (accepted version subject to English editing)
Introduction
When a true endpoint of interest in a research is difficult to be measured because of high expense or infeasibility in a reasonable length of time, a surrogate variable is measured instead of the endpoint. Then the causal effect of a treatment or an intervention on the unmeasured endpoint is predicted by the causal effect of the treatment on the measured surrogate. There have been several criteria for reasonable surrogates proposed. Prentice (1989) first gave the statistical surrogate criterion which requires the conditional independence of the treatment and the endpoint given the surrogate. Frangakis and Rubin (2002) proposed the principal surrogate criterion which requires the property of causal necessity that no treatment effect on the surrogate implies no treatment effect on the endpoint. Lauritzen (2004) depicted the strong surrogate criterion by a causal diagram which requires that the surrogate blocks the path from the treatment to the endpoint. Gilbert and Hudgens (2008) proposed the average causal necessity and the average causal sufficiency for a reasonable surrogate. Joffe and Greene (2009) summarized related statistical approaches and discussed the relationships among these approaches. However, the above criteria cannot avoid the surrogate paradox proposed in Chen et al. (2007) . The surrogate paradox means that a treatment has a positive effect on a surrogate and the surrogate has a positive effect on an endpoint, but the treatment has a negative effect on the endpoint. Chen et al. (2007) and Ju and Geng (2010) proposed the criteria for consistent surrogates to avoid the surrogate paradox based on the causation knowledge between the surrogate and the endpoint. Wu et al. (2011) proposed sufficient conditions to predict the sign of treatment effect on the unmeasured endpoint by the sign of treatment effect on the measured surrogate based on the association knowledge between the surrogate and the endpoint. The conditions can be checked empirically by observed data if the endpoint is observed in a validation study. VanderWeele (2013) extended the results of Chen et al. (2007) and Ju and Geng (2010) to the cases where there is a direct effect of the treatment on the endpoint. All of these criteria are only for a single surrogate.
In many applications, however, a treatment or an intervention affects the endpoint through several paths, and thus a single surrogate cannot block these paths. For example, a drug may reduce a death due to AIDS through two paths, one is by decreasing HIV-1 RNA and the other is by increasing CD 4 count. In this case, only a single surrogate may not satisfy any criStatistica Sinica: Newly accepted Paper (accepted version subject to English editing) Criteria for multiple surrogates terion of the statistical, principal and strong surrogates, and both HIV-1 RNA and CD 4 count should be used as multiple surrogates for the death due to AIDS. That is, the surrogate paradox may be avoid by using two or multiple surrogates if it cannot be avoided by using a single surrogate. Joffe (2013) also suggested that it is meaningful to generalize the criteria for a single surrogate to multiple surrogates.
In this paper, we propose some criteria for multiple surrogates based on stochastic orders of random vectors. We give conditions to avoid the surrogate paradox and use the signs of treatment effects on multiple surrogates to predict the sign of treatment effect on the true endpoint. We further propose some sufficient conditions for the sign equivalence of treatment effects on the surrogates and on the true endpoint under the conditional independence of treatment and true endpoint given the multiple surrogates, which can be seen as a multiple surrogates version of Prentice's criterion. Furthermore, we illustrate how these criteria can be applied to several commonly-used models. All of these conditions required by the proposed criteria can be tested if there is a validation trial in which the endpoint is observed, and some of these conditions can also be tested if the endpoint has been observed in the control group in a previous trial with the same placebo.
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Notation and definitions
Let A denote a randomized treatment, and Y denote the true endpoint of interest. Let S 1 , . . . , S p denote p potential surrogates. If A has more than two levels, we can compare them pairwise. Without loss of generality, we suppose A has only two levels with A = 1 for an active drug and A = 0 for placebo. In this paper, we suppose that the surrogates S 1 , . . . , S p are not randomized. Thus, there may be some confounders U which affect the surrogates S 1 , . . . , S p as well as the true endpoint Y . For simplicity, we omit the observed covariate vector Z, and the results in this paper can be treated conditionally on the observed Z. We depict the causal diagram for p = 2 surrogates in Figure 1 . The double-headed arrow between S 1 and S 2 means that they are correlated. With the notation of the potential outcome model (Rubin, 1974) , let Y (a, s) denote the potential outcome of the true endpoint under the treatment A = a and the surrogate vector S = s, and let S(a) = (S 1 (a), . . . , S p (a)) and Y (a) = Y (a, S(a)) denote the potential outcomes of the surrogate vector and the true endpoint under treatment A = a, respectively. In addition, 
This assumption is the so-called "consistency assumption" (Angrist et al., 1996) . Below we first define the average causal effect (ACE).
Definition 1 (ACE). The average causal effect (ACE) of
In the definition of ACE, E(Y (a)) is the average of the potential outcomes which would be obtained if treatment A = a were received by all individuals including those actually receiving the other treatment A ̸ = a.
Next we define the distribution causal effect (DCE), which is a finer causal measurement than ACE for a continuous response Y .
Definition 2 (DCE). The distribution causal effect (DCE) of A on Y for a specific threshold y is defined as
Similarly, we define ACE A→S i and DCE A→(S i >s) for a surrogate S i .
To assess the treatment effect on a random vector of multiple surrogates, we introduce three stochastic orders of random vectors and the related inequalities (Shaked and Shanthikumar, 2007) . Denote a value by a 
three upper sets for n = 2.
Definition 3.
For two random vectors X and Y, we say: Further we define the strict order and the equal order below.
Definition 4.
For two random vectors X and Y, we say:
1. X is strictly smaller than Y in the usual stochastic order (denoted
2. X is equal to Y in the usual stochastic order (denoted by X = st Y)
the placebo A = 0 has an equal effect on the surrogate vector.
Now we present a numerical example to illustrate the surrogate paradox even when two surrogates blocked all the pathways from the treatment to the endpoint. Consider a causal diagram as shown in Figure 2 , where all variables are binary. Let A be the treatment variable, Y be the true endpoint, S 1 and S 2 be the two surrogate variables blocking all the pathways, and U be an unobserved confounder affecting S 1 , S 2 and Y . The probabilities are given as follows: P (A = 1) = 0.767, P (U = 1) = 0.639, the conditional probabilities P (S 1 = 1|A, U ) and P (S 2 = 1|A, U ) given in Table 1 , and P (Y = 1|S 1 , S 2 , U ) given in Table 2 . 
and the causal effects of a surrogate on the endpoint Y conditional on the other surrogate
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We can find that the treatment A has positive effects on both surrogates S 1 and S 2 , that each surrogate has a positive effect on the endpoint Y conditional on the other surrogate, but that the treatment A has a negative effect on the endpoint Y .
Further we illustrate that the surrogate paradox cannot be avoided even if the surrogate vector S(1) is larger than S(0) in the usual stochastic order, which means that the treatment A has the stronger positive effect on the surrogate vector S. From the given causal diagram and probabilities, we get the distribution of (S 1 (0), S 2 (0)) and (S 1 (1), S 2 (1)) as shown in Table   3 . We have (S 1 (1),
As shown above, we can see that the surrogate paradox still happens
In the next section, we propose the criteria for avoiding the surrogate paradox.
Criteria for multiple surrogates without models
In this section, we shall discuss the conditions for using multiple surrogates to avoid the phenomena of the surrogate paradox. Based on the knowledge of the association between the endpoint and the surrogates, we
Criteria for multiple surrogates Table 3 : Distributions of (S 1 (0), S 2 (0)) and (S 1 (1), S 2 (1))
first discuss the conditions for the implication relationships between the signs of the treatment effects on the observed surrogates and on the unobserved endpoint. Then we give the conditions for the equivalence relationships between the signs.
Implication relationships between the signs of treatment effects on surrogates and on endpoint
We first consider the case with the knowledge on the expectation of the endpoint Y conditional on the surrogates S and treatment A. For simplicity,
Theorem 1. Suppose that we have the knowledge on the conditional expectation f (s, a):
(1) Either f (s, 1) or f (s, 0) is a nonconstant increasing function of s, and
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Then S(1) ≥ st S(0) implies ACE A→Y ≥ 0, and S(1) > st S(0) implies
The condition (1) Then Further for the case of two binary surrogates, we have the following result.
Corollary 3. Suppose that we have the following knowledge:
(1) Either f (s, 1) or f (s, 0) is a nonconstant increasing function of s, 
is a univariate non-negative increasing (decreasing) function of s i , and
Then the ACE of
In the above theorem, we use 'increasing (decreasing) (1) Either g y (s, 1) for any y or g y (s, 0) for any y can be factorized as 
Equivalence relationships between signs of treatment effects on the surrogates and endpoint
In the previous subsection, we present only the implication relationships from the signs of treatment effects on the multiple surrogates to the sign of treatment effect on the endpoint. However, there may be some cases where the treatment has a positive effect on the endpoint, but it cannot be predicted by the signs of treatment effects on these surrogates. In this subsection, we discuss the conditions for the equivalence relationships between the signs of treatment effects on the surrogates and on the endpoint. 
Theorem 3. Suppose that
To predict the sign of ACE on the endpoint Y in the above theorem, we use the signs of DCEs on the surrogates S. For the normal and binary surrogates ((b) and (c) in Condition (3)), the signs of DCE and ACE on S are the same. But their signs may be different for (a), although the requirement of the normal and binary surrogates can be relaxed to the surrogates from one-parametric exponential family.
The conditions in Theorem 3 ensure not only that positive treatment effects on all surrogates imply a positive treatment effect on the endpoint but also that a positive treatment effect on the endpoint also implies positive treatment effects on the surrogates. 
Criteria for multiple surrogates with models
In this section, we discuss the conditions for predicting the sign of treatment effect on the unobserved endpoint when the endpoint Y has the generalized additive model, Cox's proportional hazard model and the hazard additive model.
Generalized additive model
First we consider the following generalized additive model for the ex-
where g is an known link function, and each f i may be a function which may be parametric, non-parametric or semi-parametric. It is an extension of the generalized linear model, and particularly it includes linear model, logistic model and Probit model.
Corollary 5. For the generalized additive model, suppose that (1) g is a strictly increasing function, and
Criteria for multiple surrogates (2) each f i is an increasing function, i = 0, 1, . . . , p.
Then the ACE of A on Y is non-negative if S(1) ≥ st S(0). Furthermore if

S(1) > st S(0) and f i (1 ≤ i ≤ p) is not constant in s i for some i, then the ACE of A on Y is positive.
For the generalized additive model, the conditions for the equivalence relationship between the effect signs of A on S and Y are given below.
Corollary 6. For the generalized additive model, suppose that (1) Prentice's criterion Y A | S holds,
(2) g is a strictly increasing function, 
. . , p) is an increasing function, and there is some
This model (1.2) includes the linear model and the log additive model.
Corollary 7. For the model (1.2), suppose that (a) g ij is a univariate strictly increasing (decreasing) non-negative function
for every i and j, and
Then the ACE of A on Y is non-negative if S(1) ≥ uo (≤ lo )S(0).
Hazard Models
In this subsection, we consider two hazard models: the Cox proportional hazard model
and the hazard additive model
where g i 's are known functions and λ 0 (y) is baseline hazard function.
Corollary 8. For the Cox proportional hazard model holds, suppose that
(1) g i (s i ) is a univariate decreasing functions for i = 1, . . . , p, and
Then DCE of A on Y is non-negative if S(1) ≥ st S(0).
Corollary 9. For the hazard additive model holds, suppose that
(1) g i (s i )'s are all univariate decreasing (increasing) functions, and
Then DCE of A on Y is non-negative if S(1) ≥ uo (≤ lo )S(0).
For both hazard models, the conditions for the equivalence relationship between the effect signs of A on S and Y are given below.
Corollary 10. For both hazard models, suppose that
(1) Y A | S, which is equivalent to g 0 (1) = g 0 (0), 
Simulation studies
In this section, we illustrate our results and the sensitivity about their conditions by simulation studies with two surrogates. For two normal surrogates conditional on treatment, as shown in Corollary 2, we have 
is not an increasing function in a,
is not an increasing function in s 2 .
In our simulations, we used a binary randomized treatment A, two normal surrogates S 1 and S 2 , a continuous endpoint Y and an unobserved confounder U following a normal distribution. The data generation mechanism is
2. the unobserved confounder U ∼ N (0, 1),
The covariance matrices of (S 1 , S 2 ) conditional on A = 1 and A = 0 are the same, as required in Corollary 2. For each sample, the parameters α 1 , α 2 , β 1 , β 2 , γ 1 , γ 2 , γ 3 , γ 4 and ρ are randomly generated from the following uniform distributions
If S 1 and S 2 block all the pathway from A to Y , then there is no direct 3, 3] and P (γ 1 = 0) = 0, there may be direct effect from A to Y in our simulations.
We replicated 100,000 simulation runs with sample sizes 100, 200, 300
and 400. For each simulation, we checked the conditions in Corollary 2 to see which one of the above six scenarios happens, and we rejected the simulation if it does not belong to any of the six scenarios. For each scenario of the accepted simulations, we calculated the percentage of the simulations which have positive ACE A→Y in this scenario.
From the data generating process, we can get
Thus the linear model E(Y
Although we could check the conditions in Corollary 2 based on all the parameters generated in each simulation, we use statistical tests on b 1 , b 2 and b 3 in simulations to mimic what would happen in practice where these parameters are unknown. We judge that the conditions (1) and (2) 
0 : ACE A→S 2 ≤ 0 and H
0 : ACE A→Y ≤ 0 using t-test at the significance level 0.01, respectively. Note that for our simulations, we tested H
0 to check whether a significant ACE A→Y > 0 could be obtained from the simulated data if Y were observed, although we cannot test H
0 since Y is generally not observed in the real trials. We summarize Statistica Sinica: Newly accepted Paper (accepted version subject to English editing)
Criteria for multiple surrogates the percentages for correctly predicting a significant ACE A→Y > 0 for the six scenarios in Table 3 . We can see that for the scenario 1 where all the conditions in Corollary 2 are satisfied significantly, a significant ACE A→Y is predicted at a high percentage in the simulations. It may be because we required that all conditions for ACE A→Y > 0 were simultaneously significant in each simulation. For other scenarios where only one of these conditions is violated, the proportions of ACE A→Y > 0 are much smaller than 100%, which means we cannot predict a significant ACE A→Y > 0 correctly. This shows a strong evidence that the conditions of Corollary 2 are essential to predict a positive treatment effect on the unobserved endpoint.
Application on Campaign Finance Reform Experiment Data
To illustrate the application of our criteria for multiple surrogates, we reanalyze the data set of Druckman and Nelson's experiment (Druckman and Nelson, 2003) . This data set is used to study how citizens' conversa- Because A is randomized, we can identify ACE A→M , ACE A→W and 
Discussion
The statistical surrogate criterion, the principal surrogate criterion, the strong surrogate criterion and the consistent surrogate criterion are only for a single surrogate. In real applications, there are often multiple causal paths from the treatment or exposure to the endpoint, and thus the conditions required in the above criteria cannot be satisfied and should be extended to the cases with multiple surrogates. It has been noticed that the statistical surrogate criterion, the principal surrogate criterion and the strong surro-gate criterion cannot avoid the surrogate paradox. Although the consistent surrogate criteria proposed by Chen et al. (2007) , Ju and Geng (2010) and Vanderweele (2013) can avoid the surrogate paradox, they are for a single surrogate and the conditions in their criteria involve unobserved confounders between a surrogate and an endpoint, and thus they are untestable even if the endpoint is observed. In this paper, we proposed the criteria for multiple surrogates which do not involve unobserved confounders, and thus these conditions can be tested if there are validation trials in which the endpoint is observed. Further the monotonicity of f (s, 0) required in the condition (1) in our theorems and corollaries can be checked if the same control group was used in the previous trials where the endpoint Y was observed. It should be noticed that the monotonicity is an important additional condition for Prentice's statistical criterion to avoid the surrogate paradox.
We proposed a testing approach for easily checking the stochastic orders when the surrogate vector is normal or has only two binary surrogates. The approach can be generated to the case of a surrogate vector with mixture of normal and two binary surrogates. For more general cases, the nonparametric approaches such as a goodness fitting test should be considered to test the stochastic orders.
In this paper, we only discuss the criteria for multiple surrogates to predict the signs of treatment effects on the unobserved endpoint. In some real applications, if an additional validation sample with observed endpoint Y from a previous clinical trial is also available, then we can try to quantitatively evaluate the treatment effects on the endpoint. The validation sample from the previous trial can be used to provide the information on E(Y |s, a), such as its point estimate or its prior distribution. Then we can use the data from the current trial with only surrogates observed but the endpoint missing or combine the data from the current and previous trials together to obtain more efficient estimates of p(s|a) and thus more efficient
estimates of E(Y |a) for a = 0, 1. Using the estimates, we can quantitatively evaluate the treatment effects ACE A→Y and DCE A→(Y >y) .
For the multiple hypothesis testing on the treatment effects on multiple surrogates, the false discover rate should be considered in our future works. 
Appendix: Proofs of theorems and corollaries
E(ϕ(X)) < E(ϕ(Y)).
provided the expectations exist.
We can find the proof of the first part of the lemma in Shaked and Shanthikumar (2007) . Below we prove the second part.
Proof of Lemma 1. Recall that
We have
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Let W (c) denote {x | ϕ(x) > c}. Notice that W (c) is an upper set since that ϕ(x) is an increasing function implies that for x ∈ W (c), any y ≽ x also implies ϕ(y) > c, which leads to y ∈ W (c). are all null or negative, the corresponding results can be derived. Here we completed the proof.
